Nektar Therapeutics (NKTR)
NASDAQ: NKTRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NKTR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.03B
- EPS (TTM)
- -$22.47
- Dividend yield
- None
- 52-week range
- 30.13 – 109.00
- Day range
- 30.13 – 32.35
- Volume / Avg
- 1.02M / 1.12M
- Beta
- —
- Shares outstanding
- 34.21M
52-week range
NKTR stock today
Shares of Nektar Therapeutics (NKTR) finished lower on Nov 20 at $30.20, a drop of 7.19% or $2.34 per share, versus the S&P 500's 3.70% decline. Shares are 72.3% below their 52-week high of $109.00, set on Apr 20, 2026 and 0.2% above the 52-week low of $30.13, near the bottom of the past year's range. NKTR is down 28.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.4%.
Nektar Therapeutics has posted a net loss over the last twelve months (EPS of -$22.47), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Nektar Therapeutics
Company profileNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Howard W. Robin
- Headquarters
- San Francisco, CA
- Employees
- 63
- Website
- nektar.com
Financial highlights
Full financialsIn fiscal 2025, Nektar Therapeutics generated $55.2 million in revenue, down 43.9% from fiscal 2024, its first annual decline since 2023. Nektar Therapeutics reported a net loss of $164.1 million, compared with a loss of $119.0 million a year earlier. Gross margin was 100.0% (up from 68.8%) and operating margin -253.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $55.23M | $98.43M | $90.12M | $92.06M | $101.91M |
| Growth | -43.89% | +9.22% | -2.10% | -9.67% | -33.36% |
| Net income | $-164.08M | $-118.96M | $-276.06M | $-368.20M | $-523.84M |
| EPS (diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$131.92+336.82%
- Strong buy 1
- Buy 10
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.85 vs $-2.16
- Surprise
- +14.35%
NKTR news
All NKTR news- Nektar (NKTR) Q3 2026 Earnings Call TranscriptNasdaq
- NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock DownNasdaqNKTR, LLY, COLL
- Nektar Therapeutics Announces Third Quarter 2026 Financial ResultsPR Newswire
- Nektar Therapeutics Q3 2026 Earnings PreviewSeeking Alpha
- Nektar Therapeutics to Participate in Two Investor Conferences in NovemberPR Newswire
- Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial MarketsPR Newswire
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?NasdaqNKTR, REGN, SNY, LLY
Nektar Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CTYCity Therapeutics Inc. | 19.32 | +5.29% | $1.03B | vs NKTR |
| ANROAlto Neuroscience Inc. | 25.37 | -4.30% | $1.02B | vs NKTR |
| JBIOJade Biosciences Inc. | 15.31 | +1.66% | $1.06B | vs NKTR |
| KARDKardigan Inc. | 11.54 | -7.83% | $1.08B | vs NKTR |
| OMEROmeros Corporation | 13.21 | -5.71% | $983.66M | vs NKTR |
| SPTXSeaport Therapeutics Inc. | 18.05 | -1.47% | $966.23M | vs NKTR |
| CYRXCryoPort Inc. | 19.05 | -2.56% | $964.87M | vs NKTR |
| AAPGAscentage Pharma Group International American Depository Shares | 11.97 | -3.78% | $1.12B | vs NKTR |
Indexes, lists and sector
Nektar Therapeutics stock FAQ
What is Nektar Therapeutics's stock price today?
NKTR last traded at $30.20 as of Nov 20, 4:00 PM EST, down 7.19% on the day. Prices are delayed at least 15 minutes.
Does Nektar Therapeutics pay a dividend?
No. Nektar Therapeutics does not currently pay a regular cash dividend.
Who is Nektar Therapeutics's CEO?
Mr. Howard W. Robin is the chief executive officer of Nektar Therapeutics, which has about 63 employees.
Has NKTR ever split its stock?
Yes. The most recent NKTR stock split was a 1-for-15 split on Jun 9, 2025, one of 2 splits on record.
What is the NKTR 52-week high?
The 52-week high for NKTR is $109.00 and the 52-week low is $30.13. The stock is currently 72.3% below its high.